Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 3/20 | 0.49 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30387843 | 1.00 | SNCA (0.50) | SNCAMETAP2TERTHSD17B1HSD17B2 | |
| SCHEMBL12871629 | 0.81 | STIM1 (0.56) | HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14154999 | 0.80 | MAPT (0.56) | SNCAMETAP2TERTNPC1RAB9A | |
| SCHEMBL17336646 | 0.79 | RAB9A (0.56) | METAP2HSD17B1HSD17B2NPC1RAB9A | |
| SCHEMBL12171872 | 0.77 | STIM1 (0.52) | HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26095108 | 0.77 | PTK2 (0.44) | HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30388093 | 0.77 | PTK2 (0.44) | HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26096199 | 0.74 | SNCA (0.86) | SNCAMETAP2TERTNPC1RAB9A | |
| SCHEMBL15425056 | 0.74 | SNCA (0.86) | SNCAMETAP2TERTNPC1RAB9A | |
| SCHEMBL12172050 | 0.74 | TP53 (0.53) | HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265453-A | Protein aggregation inhibiting compounds for plant disease control | 马克斯·普朗克科学促进学会 | 2024-06-28 | — | — | CN | disclosed |
| EP-4384013-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4173485-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-11-23 | — | — | US | disclosed |
| US-20200165279-A1 | PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165279-A1 | PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA | TYR, MITF, VHL | SNCA 3888/4885METAP2 1393/4885TERT 93/4885 |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | TYR, MITF, VHL | SNCA 3888/4885METAP2 1393/4885TERT 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.